Incorporation and Controlled Release of Silyl Ether Prodrugs from PRINT Nanoparticles

Citations Over TimeTop 10% of 2012 papers

Abstract

Asymmetric bifunctional silyl ether (ABS) prodrugs of chemotherapeutics were synthesized and incorporated within 200 nm × 200 nm particles. ABS prodrugs of gemcitabine were selected as model compounds because of the difficulty to encapsulate a water-soluble drug within a hydrogel. The resulting drug delivery systems were degraded under acidic conditions and were found to release only the parent or active drug. Furthermore, changing the steric bulk of the alkyl substituents on the silicon atom could regulate the rate of drug release and, therefore, the intracellular toxicity of the gemcitabine-loaded particles. This yielded a family of novel nanoparticles that could be tuned to release drug over the course of hours, days, or months.

Related Papers

• Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis.(2018)
• → Facile synthesis of silyl allenol ethers and β-silyl enones through reductive silylation of benzoylacetylenes(2022)2 cited
• → EFFORTS TO IMPROVE THE ANTI-TUMOR EFFECT OF GEMCITABINE IN HUMAN PANCREATIC CANCER(2008)
• → A Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study(2007)
• Gemcitabine alone versus gemcitabine plus carboplatin in treatment of elderly patients with advanced non-small cell lung cancer(2011)